Regorafenib belongs to the first generation of targeted drugs

Regorafenib is an oral multi-target tyrosine kinase inhibitor (TKI) that does not strictly belong to a certain "generation" of targeted drug classification systems. It is more commonly classified as a multi-target small molecule targeted therapeutic drug because it can act simultaneously on multiple signaling pathways related to tumor cell proliferation, angiogenesis and the tumor microenvironment. Unlike "first-generation" and "second-generation" drugs that specifically target a certain mutation site, regorafenib's "broad-spectrum" mechanism of action enables it to show certain efficacy in a variety of advanced solid tumors.

Regofenib mainly works by inhibitingVEGFR (vascular endothelial growth factor receptor)1-3, PDGFR, FGF R, KIT, RET, RAF and other key pathways interfere with the process of tumor neovascularization, cell proliferation and tumor metastasis. This multi-target inhibition strategy is particularly important in cancers that are refractory or resistant to other TKI drugs. For example, regorafenib is used as a back-line treatment in various tumors such as colorectal cancer, gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma.

Although regorafenib is not classified as a first-, second- or third-generation targeted drug in the traditional sense, its research and development concept represents a new development direction: shifting from high selectivity to "multi-pathway intervention" to adapt to patient groups with more heterogeneous tumors. Compared with "intergenerational" targeted drugs that are specifically used for specific genetic abnormalities such as EGFR mutations or ALK rearrangements, regorafenib has a wider scope of application and is not limited to certain mutation groups.

In summary, regorafenib does not belong to the strictly defined "generation" of targeted drugs, but is a representative of multi-target TKI drugs, which is especially suitable for the treatment of a variety of advanced or metastatic solid tumors. Its broad-spectrum inhibitory properties also make it an indispensable member of the precision tumor treatment system, especially in patients who are ineffective or relapsed with standard therapies.

Reference materials:https://www.stivarga-us.com/